Impact of allopurinol use on urate concentration and cardiovascular outcome

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Guidelines recommend that the therapeutic goal of urate‐lowering therapy (ULT) is to achieve a urate concentration of ≤6 mg dl−1. • High‐dose allopurinol is associated with reduced cardiovascular events and mortality in heart failure patients. WHAT THIS STU...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	British journal of clinical pharmacology Ročník 71; číslo 4; s. 600 - 607
Hlavní autori:	Wei, Li, Mackenzie, Isla S., Chen, Yang, Struthers, Allan D., MacDonald, Thomas M.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Oxford, UK Blackwell Publishing Ltd 01.04.2011 Blackwell Blackwell Science Inc
Predmet:	Aged Aged, 80 and over allopurinol Allopurinol - therapeutic use Biological and medical sciences Cardiovascular Diseases - etiology Cardiovascular Diseases - mortality cardiovascular event Cohort Studies Female Gout - complications Gout - drug therapy Gout - mortality Gout Suppressants - therapeutic use Hospitalization - statistics & numerical data Humans Hyperuricemia - complications Hyperuricemia - drug therapy Hyperuricemia - mortality Male Medical sciences mortality Pharmacoepidemiology Pharmacology. Drug treatments Proportional Hazards Models Risk Factors Time Factors Treatment Outcome United Kingdom urate Uric Acid - analysis Hypouricemic agent Prognosis Enzyme Allopurinol Mortality cardiovascular event Enzyme inhibitor Cardiovascular disease Pyrazolopyrimidine derivatives urate Xanthine oxidase Oxidoreductases Circulatory system
ISSN:	0306-5251, 1365-2125, 1365-2125
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!